This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-03. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
=== Condensation from plasma === Nanoparticles of pure metals, oxides, carbides, and nitrides, can be created by vaporizing a solid precursor with a thermal plasma and then condensing the vapor by expansion or quenching in a suitable gas or liquid. The plasma can be produced by dc jet, electric arc, or radio frequency (RF) induction. The thermal plasma can reach temperatures of 10.000 K and can thus also synthesize nanopowders with very high boiling points. Metal wires can be vaporized by the exploding wire method. In RF induction plasma torches, energy coupling to the plasma is accomplished through the electromagnetic field generated by the induction coil. The plasma gas does not come in contact with electrodes, thus eliminating possible sources of contamination and allowing the operation of such plasma torches with a wide range of gases including inert, reducing, oxidizing, and other corrosive atmospheres. The working frequency is typically between 200 kHz and 40 MHz. Laboratory units run at power levels in the order of 30–50 kW, whereas the large-scale industrial units have been tested at power levels up to 1 MW. As the residence time of the injected feed droplets in the plasma is very short, it is important that the droplet sizes are small enough in order to obtain complete evaporation.
Malaysia is a federal constitutional elective monarchy and the only federal country in Southeast Asia. The system of government is closely modelled on the Westminster parliamentary system, a legacy of British rule. The head of state is the King, whose official title is the Yang di-Pertuan Agong. The King is elected to a five-year term by and from among the nine hereditary rulers of the Malay states. The other four states, which have titular Governors, do not participate in the selection. By informal agreement the position is rotated among the nine, and has been held by Ibrahim Iskandar of Johor since 31 January 2024. The King's role has been largely ceremonial since changes to the constitution in 1994, picking ministers and members of the upper house. Legislative power is divided between federal and state legislatures. The bicameral federal parliament consists of the lower house, the House of Representatives and the upper house, the Senate. The 222-member House of Representatives is elected for a maximum term of five years from single-member constituencies. All 70 senators sit for three-year terms; 26 are elected by the 13 state assemblies, and the remaining 44 are appointed by the King upon the Prime Minister's recommendation. The parliament follows a multi-party system and the government is elected through a first-past-the-post system. Parliamentary elections are held at least once every five years.
=== Polished === Mirror polished stainless-steel belts to produce several types of thin film and ceramic sheets. The belts are available in thickness from 0.60 to 2.00 mm (0.02362 to 0.0787 in.) with thickness variation less than or equal to 80 μm. Polished steel belts are produced endlessly or as open-length belts.
== Adverse effects == During the trials there were 5 deaths from acute liver failure and 2 other patients were saved from death by receiving a liver transplant. The toxicity of FIAU was notably delayed as the severe effects became apparent after 13 weeks of treatment. The specific toxic symptoms include: fatigue, skin rash, nausea, bone marrow suppression, seizures, pain in the arms and legs, hepatic (liver) failure (with mild jaundice), lactic acidosis (severe accumulation of lactic acid in the blood), pancreatitis, micro versicular steatosis (marked accumulation of the fat within the cells of the liver), myopathy and peripheral neuropathy. The FIAU is a clear example of direct drug-induced mitochondrial toxicity. Besides being incorporated into the viral DNA, FIAU is also incorporated into mitochondrial DNA. As FIAU is inserted into the growing chain of mitochondrial DNA replication. This leads to an inability of mitochondrial DNA polymerase γ to (further) replicate the DNA. There is a lack of DNA to provide ‘instructions’ to the mitochondria, resulting in reduction of mitochondrial respiration and the activity of mitochondrial respiratory complexes. The mitochondria no longer produce sufficient energy, causing lactic acid to form rapidly. The acute liver failure is a direct result of this cascade. The liver is an energy-intensive organ and thus the failure of its cellular power plants will quickly lead to physical decay. But this damage is not limited to only the liver, as mitochondria are found all throughout the body.
Sources: en.wikipedia.org
Sodium-22 is a radioactive isotope of sodium, undergoing positron emission to 22Ne with a half-life of 2.6019 years. 22Na is being investigated as an efficient generator of "cold positrons" (antimatter) to produce muons for catalyzing fusion of deuterium. It is also commonly used as a positron source in positron annihilation spectroscopy.
Perhaps the best-known hypothesis involving mercury and autism involves the use of the mercury-based compound thiomersal, a preservative that has been phased out from most childhood vaccinations in developed countries including the US and EU. There is no scientific evidence for a connection between thiomersal and autism, but parental concern about a relationship between thiomersal and vaccines led to decreasing rates of childhood immunizations and increasing likelihood of disease outbreaks in the 1990s. In 1999, the U.S. Public Health Service recommended that thiomersal be removed from childhood vaccines. By 2002, the flu vaccine was the only childhood vaccine using thiomersal. The removal of thiomersal did not decrease autism rates in any country that removed thiomersal from their childhood vaccines. A causal link between thiomersal and autism has been rejected by international scientific and medical professional bodies including the American Medical Association, the American Academy of Pediatrics, the American College of Medical Toxicology, the Canadian Paediatric Society, the U.S. National Academy of Sciences, the Food and Drug Administration, Centers for Disease Control and Prevention, the World Health Organization, the Public Health Agency of Canada, and the European Medicines Agency.
=== Gold Cup runners-up and the 2001 Copa América (2000–2001) === Colombia made their first appearance at the CONCACAF Gold Cup as invited guests in 2000, beating Jamaica 1–0 through Gonzalo Martínez and losing 2–0 to Honduras in a three-team group, both matches played at the Miami Orange Bowl. In the quarter-final on 19 February they twice came from behind against the hosts the United States — Faustino Asprilla cancelling out Brian McBride and Gerardo Bedoya equalising in the 81st minute after Chris Armas had scored — to draw 2–2 after extra time, then won the shootout 2–1 in a sequence in which six of the nine attempts failed. A 2–1 semi-final win over Peru at Qualcomm Stadium followed, an own goal by Marcial Salazar and a Víctor Bonilla strike putting Colombia through before a crowd of 3,402. In the final at the Los Angeles Memorial Coliseum on 27 February, Canada won 2–0 through a Jason de Vos header in first-half stoppage time and a Carlo Corazzin penalty, before 6,197 spectators.
Benzene at The Periodic Table of Videos (University of Nottingham) International Chemical Safety Card 0015 USEPA Summary of Benzene Toxicity NIOSH Pocket Guide to Chemical Hazards Benzene from PubChem Dept. of Health and Human Services: TR-289: Toxicology and Carcinogenesis Studies of Benzene Video Recording of Sir John Cadogan giving a lecture on Benzene at the Royal Institution, 22 September 1991 Substance profile NLM Hazardous Substances Databank – Benzene
In November 1949, Pauling, Harvey Itano, S. J. Singer and Ibert Wells published "Sickle Cell Anemia, a Molecular Disease" in the journal Science. It was the first proof of a human disease being caused by an abnormal protein, and sickle cell anemia became the first disease understood at the molecular level. (It was not, however, the first demonstration that variant forms of hemoglobin could be distinguished by electrophoresis, which had been shown several years earlier by Maud Menten and collaborators). Using electrophoresis, they demonstrated that individuals with sickle cell disease have a modified form of hemoglobin in their red blood cells, and that individuals with sickle cell trait have both the normal and abnormal forms of hemoglobin. This was the first demonstration causally linking an abnormal protein to a disease, and also the first demonstration that Mendelian inheritance determines the specific physical properties of proteins, not simply their presence or absence – the dawn of molecular genetics. His success with sickle cell anemia led Pauling to speculate that a number of other diseases, including mental illnesses such as schizophrenia, might result from flawed genetics. As chairman of the Division of Chemistry and Chemical Engineering and director of the Gates and Crellin Chemical Laboratories, he encouraged the hiring of researchers with a chemical-biomedical approach to mental illness, a direction not always popular with established Caltech chemists. In 1951, Pauling gave a lecture entitled "Molecular Medicine".
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.